Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COPD patients from US IBM Marketscan database |
| ||
| COPD patients from UK CPRD GOLD database |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tiotropium bromide + Olodaterol | Drug | Tiotropium bromide + Olodaterol |
|
| Measure | Description | Time Frame |
|---|---|---|
| Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). | At index date of cohort entry (baseline; time of COPD diagnosis). |
| Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). | At index date of cohort entry (baseline; time of COPD diagnosis). |
| Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. | At index date of cohort entry (baseline; time of COPD diagnosis). |
| Age of Patients Receiving First Maintenance Treatment - US | Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported. | At index date of the first maintenance treatment |
| Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. | At index date of the first maintenance treatment |
Not provided
Inclusion criteria:
parent cohort
-- COPD diagnosis
child cohort
-- any initiation of first maintenance therapy after July 1, 2015
grandchild cohort -- any initiation of second maintenance therapy after August 2, 2015
Exclusion criteria:
- parent cohort
Not provided
Not provided
Not provided
The study population for the analysis will consist of all patients with at least one medical claim with a diagnosis code of COPD identified.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AETION inc | New York | New York | 10018 | United States |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
For more details refer to: https://www.mystudywindow.com/msw/datasharing
Not provided
Not provided
Not provided
Not provided
Patients with chronic obstructive pulmonary disease (COPD) who met all inclusion criteria and none of the exclusion criteria initiating tiotropium + olodaterol or other maintenance therapies from either IBM MarketScan (United States) or CPRD GOLD (United Kingdom) databases were included.
This retrospective cohort study used previously collected administrative healthcare data (United States data from IBM MarketScan and United Kingdom data from CPRD GOLD, a primary care database) to describe the patients characteristics and treatment patterns in patients with chronic obstructive pulmonary disease (COPD), initiating tiotropium + olodaterol or other maintenance therapies.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | US IBM Marketscan - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). |
| FG001 | UK CPRD GOLD - Overall |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Feb 22, 2019 |
Not provided
Not provided
Not provided
Not provided
|
| Sp(t)iolto® Respimat® | Device | Sp(t)iolto® Respimat® |
|
| At index date of the first maintenance treatment |
| Characteristics of Patients Receiving First Maintenance Treatment - US | Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported. | At index date of the first maintenance treatment |
| Age of Patients Receiving First Maintenance Treatment - UK | Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | At index date of the first maintenance treatment |
| Characteristics of Patients Receiving First Maintenance Treatment - UK | Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | At index date of the first maintenance treatment |
| Age of Patients Receiving Second Maintenance Treatment - US | Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported. | At index date of the second maintenance treatment |
| Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. | At index date of the second maintenance treatment |
| Characteristics of Patients Receiving Second Maintenance Treatment - US | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported. | At index date of the second maintenance treatment |
| Age of Patients Receiving Second Maintenance Treatment - UK | Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | At index date of the second maintenance treatment |
| Characteristics of Patients Receiving Second Maintenance Treatment - UK | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | At index date of the second maintenance treatment |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | At index date of the first maintenance treatment |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported. | At index date of the second maintenance treatment |
| Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | At index date of the second maintenance treatment |
| Days Between Index and Initiation of First Maintenance Therapy - US | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. | From index date until initiation of first maintenance, up to 3368 days before this study started. |
| Days Between Index and Initiation of First Maintenance Therapy - UK | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | From index date until initiation of first maintenance therapy, up to 9795 days before this study started. |
| Days Between First and Second Maintenance Therapy - US | Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported. | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started. |
| Days Between First and Second Maintenance Therapy - UK | Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started. |
All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). |
| COMPLETED |
|
| NOT COMPLETED |
|
All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018).
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | US IBM Marketscan - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). |
| BG001 | UK CPRD GOLD - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). | Posted | Mean | Standard Deviation | Years | At index date of cohort entry (baseline; time of COPD diagnosis). |
|
|
| ||||||||||||||||||||||||||||
| Primary | Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - UK | Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the the United Kingdom (UK) CPRD GOLD database was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015). | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). | Posted | Mean | Standard Deviation | Years | At index date of cohort entry (baseline; time of COPD diagnosis). |
| ||||||||||||||||||||||||||||||
| Primary | Charlson Comorbidity Index (CCI) at the Time of COPD Diagnosis | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan (contained data collected from January 1, 2008 to March 31, 2018) and the United Kingdom (UK) CPRD GOLD databases (contained data collected from November 21, 1987 to June 30, 2018). Results were reported by overall and by stratified groups according to Tiotropium + Olodaterol approval date for US and UK datasets, respectively. | Posted | Mean | Standard Deviation | Score on a scale | At index date of cohort entry (baseline; time of COPD diagnosis). |
| ||||||||||||||||||||||||||||||
| Primary | Age of Patients Receiving First Maintenance Treatment - US | Age of chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Mean | Inter-Quartile Range | Years | At index date of the first maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Charlson Comorbidity Index (CCI) of Patients Receiving First Maintenance Treatment - US | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Mean | Inter-Quartile Range | Score on a scale | At index date of the first maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Characteristics of Patients Receiving First Maintenance Treatment - US | Characteristics of patients receiving first maintenance treatment among chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United States (US) IBM MarketScan database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the first maintenance treatment |
| |||||||||||||||||||||||||||||||
| Primary | Age of Patients Receiving First Maintenance Treatment - UK | Age of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Years | At index date of the first maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Characteristics of Patients Receiving First Maintenance Treatment - UK | Characteristics of patients receiving first maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the first maintenance treatment |
| |||||||||||||||||||||||||||||||
| Primary | Age of Patients Receiving Second Maintenance Treatment - US | Age of patients receiving second maintenance treatment from the United States (US) IBM MarketScan database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Years | At index date of the second maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Charlson Comorbidity Index (CCI) of Patients Receiving Second Maintenance Treatment - US | The Charlson Comorbidity Index (CCI) was a method of categorizing comorbidities of patients based on the International Classification of Diseases diagnosis. The CCI score ranged from 0 (better outcome) to 21 (worse outcome). The higher the score, the more fragile/ill the patient was. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Score on a scale | At index date of the second maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Characteristics of Patients Receiving Second Maintenance Treatment - US | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United States (US) IBM MarketScan database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the second maintenance treatment |
| |||||||||||||||||||||||||||||||
| Primary | Age of Patients Receiving Second Maintenance Treatment - UK | Age of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Years | At index date of the second maintenance treatment |
| ||||||||||||||||||||||||||||||
| Primary | Characteristics of Patients Receiving Second Maintenance Treatment - UK | Characteristics of patients receiving second maintenance treatment from chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the second maintenance treatment |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - US | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the first maintenance treatment |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of First Maintenance Therapy - UK | Number of participants with zero exacerbations in the year prior to the start of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the first maintenance treatment |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - US | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the second maintenance treatment |
| |||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Zero Exacerbations in the Year Prior to the Start of Second Maintenance Therapy - UK | Number of participants with zero exacerbations in the year prior to the start of second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Count of Participants | Participants | At index date of the second maintenance treatment |
| |||||||||||||||||||||||||||||||
| Secondary | Days Between Index and Initiation of First Maintenance Therapy - US | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy the United States (US) IBM MarketScan database was reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium + Olodaterol; 21 May 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Days | From index date until initiation of first maintenance, up to 3368 days before this study started. |
| ||||||||||||||||||||||||||||||
| Secondary | Days Between Index and Initiation of First Maintenance Therapy - UK | Days between index and initiation of first maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their first maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their first maintenance therapy at the time of or after the launch date of Sp(t)iolto (referred to as Tiotropium+Olodaterol; 1 July 2015), and were free from asthma. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Days | From index date until initiation of first maintenance therapy, up to 9795 days before this study started. |
| ||||||||||||||||||||||||||||||
| Secondary | Days Between First and Second Maintenance Therapy - US | Days between first and second maintenance therapy among the chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy the United States (US) IBM MarketScan database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018) initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Days | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 1020 days before this study started. |
| ||||||||||||||||||||||||||||||
| Secondary | Days Between First and Second Maintenance Therapy - UK | Days between first and second maintenance therapy among chronic obstructive pulmonary disease (COPD) patients initiated their second maintenance therapy in the United Kingdom (UK) CPRD GOLD database were reported. | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018) initiated their second maintenance therapy at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma prior to initiation of first maintenance therapy. Results were reported by overall and by stratified groups according to therapies. | Posted | Median | Inter-Quartile Range | Days | From the index date of first maintenance initiation until the initiation of the second maintenance therapy, up to 10133 days before this study started. |
|
Not provided
This study was based on the use of secondary data without access to individual patient data. Adverse events were not collected. Zeros in the numbers of participants at risk and affected in the "All-Cause Mortality", "Serious Adverse Events", and "Other Adverse Events" sections stand for adverse event was not collected and not available for this study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | US IBM Marketscan - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | UK CPRD GOLD - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results.
Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days.
BI may request a delay of the publication in order to protect BI's intellectual property rights.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim Call Center | Boehringer Ingelheim | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
| Jun 21, 2021 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069447 | Tiotropium Bromide |
| C549647 | olodaterol |
| ID | Term |
|---|---|
| D012602 | Scopolamine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
| D009930 | Organic Chemicals |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
Not provided
Not provided
|
|
|
|
| OG002 | US IBM Marketscan - COPD Diagnosis After Tio+Olo Approval | Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United States (US) IBM MarketScan database (contained data collected from January 1, 2008 to March 31, 2018). Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 21 May 2015 were included in this group. |
| OG003 | UK CPRD GOLD - Overall | All chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). |
| OG004 | UK CPRD GOLD - COPD Diagnosis Before Tio+Olo Approval | Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). Only patients who were diagnosed COPD before the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group. |
| OG005 | UK CPRD GOLD - COPD Diagnosis After Tio+Olo Approval | Cohort of chronic obstructive pulmonary disease (COPD) patients meeting all selection criteria from the United Kingdom (UK) CPRD GOLD database (contained data collected from November 21, 1987 to June 30, 2018). Only patients who were diagnosed COPD after the approval of Tiotropium + Olodaterol (Tio+Olo) in 1 July 2015 were included in this group. |
|
|
| OG002 | US IBM Marketscan - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | US IBM Marketscan - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group |
|
|
| OG002 | US IBM Marketscan - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | US IBM Marketscan - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group |
|
|
| OG002 | US IBM Marketscan - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | US IBM Marketscan - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group. |
| OG005 | US IBM Marketscan - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group. |
| OG005 | US IBM Marketscan - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group. |
| OG005 | US IBM Marketscan - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | US IBM Marketscan - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group. |
| OG005 | US IBM Marketscan - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | US IBM Marketscan - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 1MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 1MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 1MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 1MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 1MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 1MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | US IBM Marketscan - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | US IBM Marketscan - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | US IBM Marketscan - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists(LAMA+LABA) were included in this group. |
| OG005 | US IBM Marketscan - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | US IBM Marketscan - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | US IBM Marketscan - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United States (US) IBM MarketScan database initiated their second maintenance therapy (2MT) and were free from asthma prior to initiation of first maintenance therapy. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|
| OG002 | UK CPRD GOLD - 2MT - LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists (LABA) were included in this group. |
| OG003 | UK CPRD GOLD - 2MT - LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Inhaled Corticosteroid (LABA+ICS) were included in this group. |
| OG004 | UK CPRD GOLD - 2MT - LAMA+LABA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists (LABA+LAMA) were included in this group. |
| OG005 | UK CPRD GOLD - 2MT - LAMA+LABA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Long-Acting Beta-Agonists + Inhaled Corticosteroid (LAMA+LABA+ICS) were included in this group. |
| OG006 | UK CPRD GOLD - 2MT - LAMA | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their second maintenance therapy (2MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists (LAMA) were included in this group. |
| OG007 | UK CPRD GOLD - 2MT - LAMA+ICS | All chronic obstructive pulmonary disease (COPD) patients who meet all selection criteria from the United Kingdom (UK) CPRD GOLD database initiated their first maintenance therapy (1MT) at the time of or after the launch date of Tiotropium + Olodaterol, and were free from asthma. Only patients who were treated with Long-Acting Muscarinic Antagonists + Inhaled Corticosteroid (LAMA+ICS) were included in this group. |
|
|